Accessibility barriers create enrollment failures in otherwise well-designed trials. When participants cannot reach sites due to distance, transportation limitations, mobility challenges, or geographic isolation, trial timelines extend, diversity goals fail, and enrollment costs escalate. The accessibility gap, who can physically access specialized ophthalmic assessments, is where many diversity and retention strategies break down.
For sponsors and CROs conducting trials with ocular endpoints, accessibility is not just a diversity metric; it is an execution problem. Clinical trial accessibility means bringing BCVA, IOP, OCT, and specialized imaging to participants where they live, work, or congregate, rather than expecting already underserved populations to overcome additional travel barriers to reach centralized sites.
20/20 Onsite is a specialty vendor of end-to-end ophthalmic trial consultation, clinical field execution, and support. Through point-of-need delivery that reaches participants where they live, work, or congregate, 20/20 Onsite helps sponsors and CROs eliminate geographic and mobility barriers while maintaining execution quality. In ophthalmic trials supported by 20/20 Onsite, point-of-need delivery has achieved 9% dropout versus 30% industry standard, with participants traveling an average of 12 miles compared to 67 miles for traditional site-based trials, an 80.6% reduction in travel burden that directly expands accessible participation. 98% data accuracy is maintained across point-of-need environments.
The Diversity and Cost Consequences of Inaccessibility
In the United States, 40% of the population is made up of minorities. However, in clinical studies conducted in the year 2020, 75% of participants were Caucasian. This points to a severe problem in clinical trial accessibility for underrepresented communities.
Trial accessibility failures can lead to increased costs because your trial may have a higher failure rate in later phases. The trial can be delayed because of lower participation rates, too, which hikes expenses. Failure to plan for representative enrollment may increase regulatory scrutiny, create additional data expectations, or complicate approval and post-market planning.
Clinical trial accessibility failures can occur when you ask participants to travel long distances for assessments. People with disabilities may not be able to reach the location, and those from lower socioeconomic backgrounds can struggle to pay for transportation.
Trial protocol can be especially complex for ophthalmic trials. These studies rely on endpoints that require calibrated machines and trained technicians. Diversity and trial retention strategies tend to break down when accessibility becomes a concern.
Understanding the Accessibility Gap in Ophthalmic Trials
Disparities in accessibility significantly impact ophthalmic trials for several reasons.
Types of Accessibility Barriers
Clinical trial accessibility in ophthalmic trials can come down simply to travel distance. With a centralized trial, participants will need to travel. Since healthcare studies are generally conducted in urban areas, this could pose a problem for those in rural areas.
Transportation may not be available for everyone. Participants without cars might need to take buses and trains, which means investing time and money to get to the site.
There could be physical limitations, too. Older adults, people with disabilities, immunocompromised patients, and a variety of other people could find it impossible to travel long distances. They may depend on caregivers or be unable to physically manage the trip.
Logistical issues impact clinical trial accessibility, too. People with children would need to have babysitters. Participants with jobs may not be able to leave their work to meet scheduled appointments.
The Hidden Cost of Inaccessibility
Clinical trial accessibility issues can lead to the exclusion of people with disabilities. Those who live in rural areas or who have mobility problems can also struggle to participate. Insufficient diversity in the trial weakens regulatory submissions. Your study is more likely to require audits and other processes that delay your goals.
Inaccessibility impacts your bottom line, too. It can extend enrollment timelines because you may have trouble meeting your recruitment targets. Inaccessibility can also lead to higher dropout rates, causing delays that increase costs.
Ophthalmic Trial-Specific Accessibility Challenges
Ophthalmic trials pose specific accessibility problems. For one, participants may have vision issues that prevent them from driving. Traveling to the trial site may mean relying on others or public transportation.
These trials require frequent assessments. Many ophthalmic protocols require repeated assessments, such as recurring IOP checks, OCT imaging, or other endpoint-specific exams. The frequency makes the burden of travel worse.
Ophthalmic trials are usually conducted in major medical centers due to the need for specialized equipment. Participants in rural areas can be severely affected.
How Point-of-Need Execution Eliminates Accessibility Barriers
One clinical trial solution that helps address accessibility barriers is point-of-need execution.
Geographic Accessibility Through Mobile Delivery
By introducing point-of-need execution, you can bring calibrated equipment and trained technicians to your participants. Participants will not have to travel long distances to take part in the study.
Those in rural areas and underserved communities that may not have specialized medical centers nearby would not be immediately excluded from the study.
Physical Accessibility for Mobility-Limited Populations
People who rely on caregivers or public transportation due to mobility issues would not encounter accessibility problems. Point-of-need execution would bring the trial assessments to them.
Logistical Accessibility Through Flexible Execution
Point-of-need strategies provide further accessibility by being flexible. Instead of requiring participants to change their schedules to fit trial requirements, the trial can adjust to their needs. Scheduling can be in the evening or on weekends, or assessments can occur at participants' homes, workplaces, or nearby community centers.
Integration Within CRO-Led Operations
These strategies easily integrate with CRO-led operations. CROs can manage trial coordination, while the team at 20/20 Onsite handles ophthalmic endpoint delivery. You can strengthen accessibility without replacing trial management functions.
How Point-of-Need Ophthalmic Execution Supports CRO-Led Trials
In CRO-led trials, accessibility depends on more than participant outreach. It also depends on whether specialized ophthalmic assessments can be delivered consistently across sites and participant locations. Point-of-need ophthalmic execution provides CROs with a specialized partner for BCVA, IOP, OCT, fundus photography, visual fields, and other protocol-required assessments, without replacing core trial management functions.
20/20 Onsite handles ophthalmic endpoint delivery, while CRO teams continue to manage trial coordination. The result is a more accessible execution model that reduces participant burden, supports retention, and protects the quality of ophthalmic data.
Evidence: How Mobile Delivery Expands Accessible Participation
Mobile delivery has helped reduce participants' travel distance. The average is 67 miles, but mobile delivery can reduce that to 12 miles. It has achieved a dropout rate of 9% that is significantly lower than the standard trial dropout rate (30%).
Additionally, mobile delivery improves participant satisfaction. An AGTC case study examining 150 assessments across 24 states found that mobile delivery achieved a 97% participant satisfaction rate.
Accessibility Across Therapeutic Areas
Clinical trial accessibility helps participants in studies throughout many therapeutic areas.
Aging Populations (AMD, Glaucoma, Cataracts)
Older adults can struggle with vision impairment as a result of AMD, cataracts, or glaucoma. They may also have mobility issues that prevent them from traveling to a centralized site. Point-of-need strategies reduce the burden on this demographic.
Diabetic Retinopathy in Underserved Communities
Diabetic retinopathy tends to impact low-income and rural communities severely because they do not have specialized eye-care centers nearby. Mobile delivery helps expand access in these areas.
Rare Disease Populations
People with rare diseases may be spread out across the country. Mobile care addresses rare disease trial concerns because it doesn't require participants to travel to a distant centralized trial site.
Financial Impact of Accessibility Solutions
When you employ these solutions, you help participants and save money.
Cost Avoidance Through Better Accessibility
The average cost for every dropout replacement is $19,533. By reducing dropout rates, you save a significant amount of money. The enrollment process is faster, too, which is essential. Every day a trial is delayed can mean an additional $600,000 to $8 million.
Operational Efficiency Gains
With these strategies, you have single-call accountability. Coordination becomes less of a burden. Additionally, you will not face site constraints, which could be an issue with a centralized study.
Building Accessibility Into Trial Design
Accessibility strategies are most effective when integrated during protocol development.
Assess Accessibility Barriers Early in Protocol Development
Take the time to evaluate participant demographics. Check their ages, geographic distribution, mobility issues, and anything else that could be relevant. You should also identify how frequently the participants will need to receive assessments. This can give you an idea of the burden participants might face.
Choose Execution Partners With Accessibility Capabilities
When choosing an execution partner, don't look just for site coordination. You need a partner that offers point-of-need delivery. Check that they have nationwide scalability and offer ophthalmic endpoints. Be certain that the integration model will be compatible with CRO operations as well.
How 20/20 Onsite Delivers Accessible Execution
At 20/20 Onsite, we deliver accessible ophthalmic endpoint execution through specialized point-of-need delivery.
Point-of-Need Delivery Model
Our mobile vision clinics bring OCT, BCVA, IOP, fundus photography, and visual fields right to participants. We have a 48-state reach that covers community centers, homes, and workplaces.
Proven Accessibility Outcomes
20/20 Onsite maintains 98% data accuracy, achieves 97% participant satisfaction, and delivers a 9% dropout rate across point-of-need environments.
Protect Trial Accessibility Through Specialized Execution
Clinical trial accessibility problems reduce enrollment, affect study diversity, and extend timelines. With point-of-need strategies, you can eliminate mobility and travel barriers that may be affecting enrollment and retention.
Request a protocol review and accessibility risk assessment to identify where participant geography, mobility limitations, or site availability may limit enrollment speed and diversity. 20/20 Onsite can help evaluate accessibility barriers early and build point-of-need execution strategies that expand participation while protecting data quality and regulatory compliance. Schedule a consultation to get started.